See more : Veritec, Inc. (VRTC) Income Statement Analysis – Financial Results
Complete financial analysis of Cardio Diagnostics Holdings, Inc. (CDIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardio Diagnostics Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Etsy, Inc. (ETSY) Income Statement Analysis – Financial Results
- Gravita India Limited (GRAVITA.NS) Income Statement Analysis – Financial Results
- Asian Citrus Holdings Limited (0073.HK) Income Statement Analysis – Financial Results
- Shanghai Model Organisms Center, Inc. (688265.SS) Income Statement Analysis – Financial Results
- DLE Inc. (3686.T) Income Statement Analysis – Financial Results
Cardio Diagnostics Holdings, Inc. (CDIO)
About Cardio Diagnostics Holdings, Inc.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 17.07K | 950.00 | 901.00 | 0.00 |
| Cost of Revenue | 0.00 | 16.00K | 0.00 | 0.00 |
| Gross Profit | 17.07K | -15.05K | 901.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -1,584.21% | 100.00% | 0.00% |
| Research & Development | 145.18K | 40.45K | 31.47K | 1.50K |
| General & Administrative | 6.94M | 4.40M | 470.56K | 591.52K |
| Selling & Marketing | 158.51K | 92.70K | 103.32K | 5.48K |
| SG&A | 7.10M | 4.49M | 573.88K | 597.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 4.00K |
| Operating Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Cost & Expenses | 7.26M | 4.55M | 621.35K | 609.16K |
| Interest Income | 1.07K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 6.74M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 111.62K | 16.00K | 16.00K | 10.67K |
| EBITDA | -1.53M | -4.64M | -604.45K | -598.50K |
| EBITDA Ratio | -8,966.90% | -465,254.42% | -67,086.35% | 0.00% |
| Operating Income | -7.24M | -4.55M | -620.45K | -609.16K |
| Operating Income Ratio | -42,440.43% | -478,784.32% | -68,862.15% | 0.00% |
| Total Other Income/Expenses | -1.13M | -112.53K | 0.00 | 4.00K |
| Income Before Tax | -8.38M | -4.66M | -620.45K | -605.16K |
| Income Before Tax Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| Income Tax Expense | 0.00 | 112.53K | 2.00 | 0.00 |
| Net Income | -8.38M | -4.66M | -620.45K | -605.16K |
| Net Income Ratio | -49,087.81% | -490,630.00% | -68,862.15% | 0.00% |
| EPS | -0.66 | -1.51 | -0.53 | -0.06 |
| EPS Diluted | -0.66 | -1.51 | -0.53 | -0.06 |
| Weighted Avg Shares Out | 12.69M | 3.09M | 1.16M | 9.51M |
| Weighted Avg Shares Out (Dil) | 12.69M | 3.09M | 1.16M | 9.51M |
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from CMS.
Cardio Diagnostics Announces It's Exhibiting at the 2024 Onsite Employee Health Clinics Forum
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum.
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit.
Cardio Diagnostics to Participate in the Centers for Medicare and Medicaid Services' (CMS) Clinical Laboratory Fee Schedule (CLFS) Annual Meeting to Secure Medicare Payment for Its Innovative Tests
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will recommend pricing for its Epi+Gen CHD and PrecisionCHD tests, and pursue coverage via the MolDx program.
Reviewing ARCA biopharma (NASDAQ:ABIO) and Cardio Diagnostics (NASDAQ:CDIO)
Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and ARCA biopharma (NASDAQ:ABIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership,...
Cardio Diagnostics Holdings, Inc. Announces the Availability of Its Clinical Tests at Family Medicine Specialists' Retail Healthcare Clinic at Walmart Supercenter in Round Lake Beach, Illinois, That Offers Walk-In Appointments Seven Days a Week
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics' clinical blood tests are now available at FMS' newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois.
Cardio Diagnostics Announces Publication of Study Showing That its PrecisionCHD™ Test Could Save Health Insurers Over $113 Million Annually
CHICAGO--(BUSINESS WIRE)--New study finds that Cardio Diagnostics' PrecisionCHD™ test could save health insurers over $113 Million per year.
Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan
CHICAGO--(BUSINESS WIRE)--Exponential Health adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests marking a new era in personalized and preventive cardiac care.
Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre
CHICAGO--(BUSINESS WIRE)--This collaboration aims to expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.
Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology's 73rd Annual Scientific Session
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will showcase its HeartRisk and Actionable Clinical Intelligence platforms at the ACC's 73rd Annual Scientific Session.
Source: https://incomestatements.info
Category: Stock Reports